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ABSTRACT
In a steady-state GTPase activity assay, N-[3-(1H-imidazol-4-
yl)propyl)]guanidines and NG-acylated derivatives are more po-
tent and efficacious at fusion proteins of guinea pig (gpH2R-
GsS) than human (hH2R-GsS) histamine H2 receptor, coupled
to the short splice variant of Gs, GsS. Whereas Ala-271 (hH2R)
and Asp-271 (gpH2R) in transmembrane domain 7 were iden-
tified to determine the potency differences of guanidine-type
agonists, the molecular basis for the efficacy differences re-
mains to be elucidated. A homology model of the gpH2R sug-
gested that an H-bond between Tyr-17 and Asp-271 stabilizes
an active receptor conformation of the gpH2R. In the present
study, we generated a mutant hH2R-GsS with Cys-173Tyr-
17/Ala-2713Asp-271 exchanges (hH2R3gpH2R) that exhib-
ited an enhanced level of constitutive GTPase activity and
adenylyl cyclase activity compared with wild-type hH2R-GsS
and gpH2R-GsS. Potencies and efficacies of guanidines and
NG-acylguanidines were increased at this mutant receptor
compared with hH2R-GsS, but they were still lower than at
gpH2R-GsS, suggesting that aside from Tyr-17 and Asp-271
additional amino acids contribute to the distinct pharmacolog-
ical profiles of both species isoforms. Another hH2R-GsS mu-
tant with a Cys-173Tyr-17 exchange showed inefficient cou-
pling to GsS as revealed by reduced agonist-stimulated
GTPase and basal adenylyl cyclase activities. Collectively, our
present pharmacological study confirms the existence of an
H-bond between Tyr-17 and Asp-271 favoring the stabilization
of an active receptor conformation. Distinct potencies and ef-
ficacies of agonists and inverse agonists further support the
concept of ligand-specific conformations in wild-type and mu-
tant H2R-GsS fusion proteins.
The histamine H2 receptor (H2R) is a biogenic amine re-
ceptor that belongs to the class A of the family of GPCRs.
After stimulation by histamine (HA; Fig. 1, 1), the H2R
couples to Gs proteins to activate adenylyl cyclase (AC). H2Rs
mediate regulation of gastric acid secretion in parietal cells,
cardiac contractility, and myeloid cell differentiation (Del
Valle and Gantz, 1997).
N-[3-(1H-Imidazol-4-yl)propyl]guanidines are the most
potent agonists at the H2R known so far (up to 400 times
more active than HA at the guinea pig right atrium), and
they are possibly useful as positive inotropic drugs for the
treatment of severe congestive heart failure, as agents
inducing cell differentiation in acute myelogenous leuke-
mia, and as anti-inflammatory drugs (Dove et al., 2004).
Guanidines are less potent and efficient agonists at the
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H2R of human neutrophils than at the H2R of the guinea
pig right atrium (Burde et al., 1989, 1990). In a membrane
steady-state GTPase activity assay with fusion proteins of
H2R and the short splice variant of Gs, GsS, these com-
pounds are considerably more potent and efficacious at
gpH2R-GsS than at hH2R-GsS (Kelley et al., 2001). Re-
cently, a novel class of NG-acylated imidazolylpropylgua-
nidines was developed (Ghorai, 2005). The introduction of
an electron-withdrawing carbonyl group adjacent to the
guanidine moiety reduces the basicity of the compounds
(pKa of 8). This structural modification does not change
the species selectivity between hH2R-GsS and gpH2R-GsS
(Xie et al., 2006a). By contrast, HA and the small H2R
agonists dimaprit (DIM; Fig. 1, 2) and amthamine (AMT;
Fig. 1, 3) do not exhibit species selectivity.
A three-dimensional homology model of the gpH2R sug-
gested that the nonconserved Asp-271 in transmembrane
domain (TM) 7 confers high potency to the guanidines, which
was subsequently confirmed by an Ala-2713Asp-271 muta-
tion in hH2R-GsS (hH2R-A271D-GsS) (Kelley et al., 2001).
However, the efficacies of guanidines at this mutant and at
hH2R/gpH2R chimeras were lower than at gpH2R, demon-
strating that guanidine efficacy depends on additional or
other interactions. As a rationale, an interhelical H-bond
between Tyr-17 in TM1 and Asp-271 was predicted from the
model, stabilizing an active guanidine-bound conformation
only in gpH2R but not in hH2R (containing Cys-17 and Ala-
271) (Kelley et al., 2001).
To test this hypothesis, we generated an hH2R-GsS mutant
with a Cys-173Tyr-17 exchange and a double mutant with
Cys-173Tyr-17 and Ala-2713Asp-271 exchanges in the se-
quence of hH2R. Sf9 cell membranes expressing mutant and
wild-type H2R-GsS were used to measure steady-state GTPase
activity, because this system was previously shown to be reli-
able and very sensitive to analyze ligand potencies and effica-
cies (Seifert et al., 1999; Milligan, 2000). due to the defined 1:1
stoichiometry of receptor and Gs in fusion proteins, ligand
potencies and efficacies in the steady-state GTPase assay are
independent of the expression levels, allowing for the compari-
son of various membrane preparations with different expres-
sion levels. We also assessed AC activity in Sf9 membranes as
a sensitive readout to compare distinct levels of constitutive
activity of mutant and wild-type H2R-GsS fusion proteins. Fig-
ure 1 shows the structures of H2R agonists examined in the
present study. Impromidine (IMP; 5), arpromidine (ARP; 6),
and BU-E-43 (7) are representatives of N-[3-(1H-imidazol-4-
yl)propyl]guanidines. Their NG-acylated derivatives contain di-
verse diarylpropanoyl (9 and 11), 3-(hetero)arylbutanoyl (8 and
10), and 3-(cyclohexylbutanoyl) (12) groups. Compound 13 con-
tains a 2-amino-4-methylthiazol-5-yl group and exhibits en-
hanced selectivity relative to the H3R (Ghorai, 2005). Com-
pounds 10 and 13 are the pure (R)-enantiomers. In addition, the
inverse agonists cimetidine (CIM; 14), ranitidine (RAN; 15),
famotidine (FAM; 16), aminopotentidine (APT; 17), and io-
doaminopotentidine (IAPT; 18) were studied (Hill et al., 1997;
Dove et al., 2004).
Fig. 1. Structures of H2R agonists and inverse agonists. 1 to 3, small H2R agonists; 4, H1R agonist with partial agonism at the H2R; 5 to 7,
guanidine-type H2R agonists; 8 to 12, N
G-acylated N-[3-(1H-imidazol-4-yl)propyl]guanidines with agonistic H2R activity; 13, (R)-N-[3-(2-amino-4-
methylthiazol-5-yl)propyl]-N-(3-phenylbutanoyl)guanidine, an H2R agonist; and 14 to 18, H2R inverse agonists.
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Materials and Methods
Materials. The generation of pGEM-3Z-SF-hH2R-GsS, pGEM-
3Z-SF-hH2R-A271D-GsS, and pVL1392-SF-hH2R-GsS was de-
scribed previously (Kelley et al., 2001). The generation of the bacu-
loviruses encoding hH2R-GsS and gpH2R-GsS was described
previously (Kelley et al., 2001; Houston et al., 2002). Compounds 8
and 11 and 13 (Ghorai, 2005; Xie et al., 2006a) and compound 12 (Xie
et al., 2006b) were prepared as described. IMP was synthesized as
described previously (Durant et al., 1978). ARP and BU-E-43 were
synthesized as described previously (Buschauer, 1989). APT and
IAPT were prepared as described previously (Hirschfeld et al., 1992).
Suprahistaprodifen was synthesized as described previously (Elz et
al., 2000). The structures of compounds were confirmed by elemental
analysis (C, H, N), 1H NMR, and mass spectrometry. Purity of
compounds was 98% as determined by high-performance liquid
chromatography or capillary electrophoresis. The anti-FLAG Ig (M1
monoclonal antibody) was from Sigma-Aldrich (St. Louis, MO), and
the anti-His6 Ig was from Clontech (Mountain View, CA). [-
32P]GTP
was synthesized through phosphorylation of GDP by enzymatic con-
version of L--glycerol phosphate to 3-phosphoglycerate following a
procedure described previously (Walseth and Johnson, 1979). [32P]Pi
(8500–9100 Ci/mmol orthophosphoric acid), [-32P]ATP (800 Ci/
mmol), and [3H]dihydroalprenolol (85–90 Ci/mmol) were from
PerkinElmer Life and Analytical Sciences (Boston, MA). All unla-
beled nucleotides, glycerol-3-phosphate dehydrogenase, triose phos-
phate isomerase, glyceraldehyde-3-phosphate dehydrogenase, and
lactate dehydrogenase were from Roche Diagnostics (Indianapolis,
IN). 3-Phosphoglycerate kinase, L--glycerol phosphate, HA, CIM,
RAN, and FAM were from Sigma-Aldrich. AMT was from Tocris
Cookson Inc. (Ballwin, MO). DIM was from Sigma/RBI (Natick, MA).
All restriction enzymes and T4 DNA ligase were from New England
Biolabs (Beverly, MA). Cloned Pfu DNA polymerase was from Strat-
agene (La Jolla, CA).
Construction of the cDNA for hH2R-C17Y-GsS. The Cys-
173Tyr-17 exchange in hH2R was generated by sequential overlap-
extension PCRs. With pGEM-3Z-SF-hH2R-GsS as template, PCR 1A
was used to amplify a DNA fragment consisting of the cleavable
signal peptide from influenza hemagglutinin (S), the FLAG epitope
(F) recognized by the M1 monoclonal antibody, and the N-terminal
portion of the hH2R. The sense primer annealed with 18 base pairs
of pGEM-3Z before the 5 end of SF. The antisense primer encoded
the sequence 5-GATCTTATATGCGGTAGAGTCTAGACAAAAGG-
AAGAGGCTG-3 to generate the Cys-173Tyr-17 exchange and a
new XbaI site (TCTAGA). In PCR 1B, the DNA sequence of the
hH2R, a hexahistidine tag, and the entire sequence of GsS was
amplified using pGEM-3Z-SF-hH2R-GsS as template. The sense
primer encoded the sequence -CTTTTGTCTAGACTCTACCGCAT-
ATAAGATCACCATCACCG-3 to generate the Cys-173Tyr-17 exc-
hange and the new XbaI site. The antisense primer annealed with
the cDNA encoding the five C-terminal amino acids of GsS, the stop
codon, and an XbaI site. In PCR 2, the products of PCR 1A and 1B
annealed in the region encoding the newly created Cys-173Tyr-17
exchange and the new XbaI site. Here, the sense primer of PCR 1A
and the antisense primer of PCR 1B were used. In that way, the
complete cDNA for the hH2R-C17Y-GsS fusion protein was
amplified. The product of PCR 2 was digested with SacI and KpnI
and cloned into pGEM-3Z-SF-hH2R-GsS digested with SacI and
KpnI. pGEM-3Z-SF-hH2R-C17Y-GsS was digested with SacI and
EcoN I and cloned into the baculovirus transfer vector pVL1392-SF-
hH2R-GsS digested with SacI and EcoNI. PCR-generated DNA seq-
uences were confirmed by extensive restriction enzyme analysis and
enzymatic sequencing.
Construction of the cDNA for hH2R-C17Y-A271D-GsS. To
generate the DNA for fusion proteins with two amino acid exchanges
Cys-173Tyr-17 and Ala-2713Asp-271, pGEM-3Z-SF-hH2R-A271D-
GsS was digested with KpnI and BglII and cloned into pGEM-3Z-
SF-hH2R-C17Y-GsS digested with KpnI and BglII. pGEM-3Z-SF-
hH2R-C17Y-A271D-GsS was digested with NcoI and BglII and
cloned into the baculovirus transfer vector pVL1392-SF-hH2R-GsS
digested with NcoI and BglII.
Generation of Recombinant Baculoviruses, Cell Culture,
and Membrane Preparation. Recombinant baculoviruses encod-
ing hH2R-C17Y-GsS and hH2R-C17Y-A271D-GsS were generated in
Sf9 cells using the BaculoGOLD transfection kit (BD Biosciences
PharMingen, San Diego, CA) according to the manufacturer’s in-
structions. After initial transfection, high-titer virus stocks were
generated by two sequential virus amplifications. Sf9 cells were
cultured in 250-ml disposable Erlenmeyer flasks at 28°C under ro-
tation at 125 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA)
supplemented with 5% (v/v) fetal calf serum (Cambrex Bio Science
Walkersville Inc., Walkersville, MD) and 0.1 mg/ml gentamicin
(Cambrex Bio Science Walkersville Inc.). Cells were maintained at a
density of 0.5 to 6.0  106 cells/ml. For infection, cells were sedi-
mented by centrifugation and suspended in fresh medium. Cells
were seeded at 3.0  106 cells/ml and infected with a 1:100 dilution
of high-titer baculovirus stocks encoding H2R-GsS fusion proteins.
Cells were cultured for 48 h before membrane preparation. Sf9
membranes were prepared as described previously (Seifert et al.,
1998a), using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride,
10 g/ml benzamidine, and 10 g/ml leupeptin as protease inhibi-
tors. Membranes were suspended in binding buffer (12.5 mMMgCl2,
1 mM EDTA, and 75 mM Tris-HCl, pH 7.4) and stored at 80°C
until use.
SDS-PAGE and Immunoblot Analysis. Membrane proteins
were separated on SDS polyacrylamide gels containing 12% (w/v)
acrylamide. Proteins were transferred onto Immobilon-P membranes
(Millipore Corporation, Bedford, MA) and reacted with M1 antibody,
or anti-His6 Ig (1:1000 each). Protein bands were visualized by en-
hanced chemoluminescence (Pierce Chemical, Rockford, IL) using
sheep anti-mouse IgG, coupled to peroxidase.
Steady-State GTPase Activity Assay. Membranes were
thawed, sedimented, and resuspended in 10 mM Tris-HCl, pH 7.4.
Assay tubes contained Sf9 membranes expressing H2R-GsS fusion
proteins (10 g of protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1
mM ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM
creatine phosphate, 40 g of creatine kinase, and 0.2% (w/v) bovine
serum albumin in 50 mM Tris-HCl, pH 7.4, and H2R ligands at
various concentrations. Reaction mixtures (80 l) were incubated for
2 min at 25°C before the addition of 20 l of [-32P]GTP (0.1 Ci/
tube). All stock and work dilutions of [-32P]GTP were prepared in 20
mM Tris-HCl, pH 7.4. Reactions were conducted for 20 min at 25°C.
Preliminary studies under basal conditions and with HA, IMP, and
ARP showed that under these conditions, GTP hydrolysis was linear.
Reactions were terminated by the addition of 900 l of slurry con-
sisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0.
Charcoal absorbs nucleotides but not Pi. Charcoal-quenched reaction
mixtures were centrifuged for 7 min at room temperature at 15,000g.
Six hundred microliters of the supernatant fluid of reaction mixtures
was removed, and 32Pi was determined by liquid scintillation count-
ing. Enzyme activities were corrected for spontaneous degradation of
[-32P]GTP. Spontaneous [-32P]GTP degradation was determined in
tubes containing all of the above-described components plus a very
high concentration of unlabeled GTP (1 mM) that, by competition
with [-32P]GTP, prevents [-32P]GTP hydrolysis by enzymatic ac-
tivities present in Sf9 membranes. Spontaneous [-32P]GTP degra-
dation was 1% of the total amount of radioactivity added using 20
mM Tris-HCl, pH 7.4, as solvent for [-32P]GTP. The experimental
conditions chosen ensured that not more than 10% of the total
amount of [-32P]GTP added was converted to 32Pi.
AC Activity Assay. AC activity in Sf9 membranes was deter-
mined as described previously (Houston et al., 2002). In brief, mem-
branes were thawed and sedimented by a 15-min centrifugation at
4°C and 15,000g to remove residual endogenous guanine nucleotides
as far as possible, and they were subsequently resuspended in bind-
ing buffer. Tubes contained Sf9 membranes expressing H2R-GsS
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fusion proteins (20 g of protein/tube), additionally 5 mMMgCl2, 0.4
mM EDTA, and 30 mM Tris-HCl, pH 7.4. Assay tubes containing
membranes and various additions in a total volume of 30 l were
incubated for 3 min at 37°C before starting reactions by the addition
of 20 l of reaction mixture containing (final) [-32P]ATP (0.3 Ci/
tube) plus 40 M unlabeled ATP, 2.7 mM mono(cyclohexyl)ammo-
nium phosphoenolpyruvate, 0.125 IU of pyruvate kinase, 1 IU of
myokinase, and 0.1 mM cAMP. Reactions were conducted for 20 min
at 37°C. Reactions were terminated by the addition of 20 l of 2.2 N
HCl. Denatured protein was sedimented by a 3-min centrifugation at
25°C and 15,000g. Sixty-five microliters of the supernatant fluid was
applied onto disposable columns filled with 1.3 g of neutral alumina
(A-1522, super I, WN-6; Sigma-Aldrich). [32P]cAMP was separated
from [-32P]ATP by elution of [32P]cAMP with 4 ml of 0.1 M ammo-
nium acetate, pH 7.0. Recovery of [32P]cAMP was 80%. Blank
values were routinely 0.01% of the total amount of [-32P]ATP
added. [32P]cAMP was determined by liquid scintillation counting.
The experimental conditions chosen ensured that not more than 1 to
3% of the total amount of [-32P]ATP added was converted to
[32P]cAMP.
Miscellaneous. Protein concentrations were determined using
the DC protein assay kit (Bio-Rad, Hercules, CA). [3H]Dihydroalpre-
nolol saturation binding was performed as described previously
(Seifert et al., 1998a). All analyses of experimental data were per-
formed with the Prism 4 program (GraphPad Software Inc., San
Diego, CA). KB values were calculated using the Cheng and Prusoff
(1973) equation. Expression levels of recombinant proteins were
determined using the GS-710 calibrated imaging densitometer and
the software tool Quantity One version 4.0.3 (Bio-Rad).
Results
Immunological Detection of Recombinant Proteins
in Sf9 Cell Membranes. In Sf9 cells hH2R-C17Y-GsS and
hH2R-C17Y-A271D-GsS were well expressed (Fig. 2, A and
B). Monomeric nonfused H2R expressed in Sf9 cells migrates
as an 33-kDa band in SDS-PAGE (Fukushima et al., 1997;
Houston et al., 2002), and the apparent molecular mass of
GsS is 45 kDa (Graziano et al., 1989). SDS-PAGE analysis
of membranes expressing hH2R-C17Y-A271D-GsS yielded
intense bands at80 kDa, recognized by both the anti-FLAG
and the anti-His6 antibodies, that coincide with the expected
apparent molecular masses of H2R-GsS monomers (Kelley et
al., 2001; Houston et al., 2002). Both bands seemed some-
what diffuse, representing different glycosylation forms of
the proteins. With the anti-His6 antibody, an additional dou-
blet band was detected at 45 kDa not recognized by the
anti-FLAG antibody, which is presumably due to a lack of
epitope exposure. By contrast, SDS-PAGE of membranes ex-
pressing hH2R-C17Y-GsS yielded strong and diffuse bands
at 40 kDa and lacked the expected bands at 80 kDa.
These bands could either represent atypically migrating gly-
cosylated forms of H2R-GsS monomers or degraded proteins.
Because the anti-FLAG Ig recognizes the N terminus and the
anti-His6 Ig the C terminus of the H2R, it can be concluded
that for either case the complete amino acid sequence of
hH2R-C17Y was expressed. Additional diffuse bands at110
kDa may correspond to GPCR dimers or higher oligomers
and were also observed in wild-type hH2R-GsS fusion pro-
teins (Kelley et al., 2001). Comparison with the peak inten-
sities of calibrated Sf9 membranes expressing the 2-adren-
ergic receptor (AR) at 7.5 pmol mg1 (as determined by
[3H]dihydroalprenolol saturation binding) revealed approxi-
mately similar expression levels of 2 pmol mg1 for hH2R-
C17Y-GsS and hH2R-C17Y-A271D-GsS.
Agonist and Inverse Agonist Effects on GTPase Ac-
tivities in Sf9 Membranes Expressing hH2R-GsS,
gpH2R-GsS, hH2R-C17Y-GsS, and hH2R-C17Y-A271D-
GsS. The basal GTPase activity of hH2R-GsS amounted to
0.66 0.09 pmol mg1 min1 (n 10). Compared with it, the
data were similar in membranes expressing gpH2R-GsS
(0.69  0.19 pmol mg1 min1; n  8; p  0.05) and hH2R-
C17Y-GsS (0.78  0.10 pmol mg
1 min1; n  9; p  0.05),
respectively, but significantly increased at hH2R-C17Y-
A271D-GsS (1.67  0.38 pmol mg
1 min1; n  9; p  0.01).
At the fusion proteins of both wild-type receptors and at
hH2R-C17Y-A271D-GsS, stimulation with 100 M HA
yielded GTPase activities 400 to 600% of the basal levels. By
contrast, at hH2R-C17Y-GsS, maximal HA GTPase activities
amounted to just 140% of the basal signal, thereby providing
an insufficiently low signal-to-noise ratio for detailed analy-
sis of agonists (Fig. 3). Thus, for a comparative analysis of
efficacies and potencies of compounds 1 to 13, only mem-
branes expressing both wild-type receptors and the double
mutant hH2R-C17Y-A271D-GsS were considered (Table 1).
The efficacies of the small agonists DIM (2) and AMT (3) were
slightly increased at gpH2R-GsS and hH2R-C17Y-A271D-
GsS, relative to hH2R-GsS. The potencies of HA (1) (Fig. 3),
DIM (2), and AMT (3) were increased at hH2R-C17Y-A271D-
GsS compared with the wild-type receptors. The H1R-selec-
tive agonist suprahistaprodifen (4) (Seifert et al., 2003) acted
as a partial agonist with similar efficacies and potencies at
hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS. In
agreement with previous studies (Kelley et al., 2001; Xie et
al., 2006a,b),N-[3-(1H-imidazol-4-yl)propyl]guanidines 5 to 7
and most of their NG-acylated derivatives 8 to 13 were
more efficacious and more potent at gpH2R-GsS than at
hH2R-GsS. Except for IMP (5) being more efficacious at
hH2R-C17Y-A271D-GsS, the efficacies of 5 to 7 were not
significantly changed at the mutant receptor compared with
Fig. 2. Immunological detection of recombinant proteins in Sf9 cells. Sf9
membranes expressing various proteins were prepared, separated by
SDS-PAGE on gels containing 12% (w/v) acrylamide, transferred onto
Immobilon P membranes, and probed with the respective Ig indicated on
top of each panel. In each lane, 10 g of membrane protein was loaded
onto the gel. Numbers on the left of membranes designate masses of
marker proteins in kilodaltons.
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wild-type hH2R-GsS. Compound 11 but not ARP (6) was
more efficacious and both were more potent at hH2R-C17Y-
A271D-GsS than at wild-type hH2R-GsS. Compounds 8 and
9 share a 2-thiazolyl moiety and were more potent at the
double mutant compared with hH2R-GsS, although for com-
pound 9 the difference was not significant. When the 2-thia-
zolyl group was replaced by a cyclohexyl group (12), the
selectivity for the mutant was lost. Taken together, the small
H2R agonists 1 to 3 were considerably more potent at hH2R-
C17Y-A271D-GsS than at the wild-type human and guinea
pig H2R-GsS. Some guanidines and N
G-acylated guanidines
displayed enhanced potencies at the mutant receptor com-
pared with hH2R-GsS. However, these compounds were all
less potent at hH2R-C17Y-A271D-GsS than at gpH2R-GsS,
and the efficacies varied between the corresponding values at
both wild-type receptors.
At wild-type H2R-GsS and hH2R-C17Y-A271D-GsS CIM
(14), RAN (15), FAM (16), APT (17), and IAPT (18) decreased
GTPase activities below basal and thus acted as inverse
agonists (Table 2). At hH2R-C17Y-A271D-GsS inverse ago-
nist efficacies of 14 to 18were significantly increased relative
to wild-type receptors. Because inverse agonists stabilize an
inactive receptor conformation (Milligan et al., 1995), the
differences in inverse agonist efficacies reflect an increased
level of constitutive activity of hH2R-C17Y-A271D-GsS rel-
ative to wild-type receptors. The magnitudes of constitutive
activity measured critically depend on the relative stoichiom-
etry of GPCR and G protein in the system (Kenakin, 2001).
Physical tethering of H2R with GsS in the fusion proteins
used provides a fixed 1:1 stoichiometry of both partners,
allowing for a direct comparison of the efficacies in an ex-
pression-independent manner (Milligan, 2000). Compounds
16 and 18 were slightly more potent at hH2R-C17Y-A271D-
GsS than at the wild-type receptors, whereas no significant
differences in the KB values were observed for 14, 15, and 17.
Regulation of AC Activities in Membranes Express-
ing hH2R-GsS, gpH2R-GsS, hH2R-C17Y-GsS, and
hH2R-C17Y-A271D-GsS. AC activities were measured in
Sf9 membranes expressing hH2R-C17Y-GsS and hH2R-
C17Y-A271D-GsS, and they were compared with results at
wild-type human and guinea pig H2R-GsS (Table 3). hH2R-
GsS and gpH2R-GsS were similarly expressed in Sf9 cells
(at 3 and 1 pmol mg1, respectively) and produced similar
basal AC activities. By contrast, basal AC activities were
increased 3-fold at hH2R-C17Y-A271D-GsS. At both mu-
tant and both wild-type receptors, 10 M GTP by itself in-
creased AC activities above the basal level (Fig. 4), indicating
constitutive activity of these receptors (Seifert et al., 1998a,b;
Gille and Seifert, 2003). Accordingly, at all four H2Rs, the
inverse agonist IAPT (18) reduced this GTP-dependent AC
activity. At hH2R-GsS and gpH2R-GsS, AC activity in-
creases by 10 M GTP achieved 73 and 77%, respectively, of
the signal increases by 10 M GTP plus 100 M HA. Strik-
ingly, at hH2R-C17Y-A271D-GsS, HA did not further en-
hance the GTP effect. Both higher basal AC activity and a
strong stimulation by GTP caused exhaustion of the limiting
Fig. 3. Concentration-dependent increase of GTPase activity by HA in
membranes expressing hH2R-GsS (f), gpH2R-GsS (), hH2R-C17Y-GsS
(F), and hH2R-C17Y-A271D-GsS (Œ). GTPase activity in Sf9 membranes
was determined as described under Materials and Methods. Reaction
mixtures contained membranes (10 g of protein/tube) expressing fusion
proteins and HA at concentrations indicated on the abscissa. Data shown
are the means  S.E.M. of three independent experiments performed in
duplicates. Data were analyzed by nonlinear regression and were best
fitted to sigmoidal concentration-response curves.
TABLE 1
Agonist efficacies and potencies at hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS in the GTPase assay
Steady-state GTPase activity in Sf9 membranes expressing hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS was determined as described under Materials and
Methods. Reaction mixtures contained Sf9 membranes expressing fusion proteins and agonists at concentrations from 1 nM to 1 mM as appropriate to generate saturated
concentration-response curves. Curves were analyzed by nonlinear regression and were best fitted to sigmoidal concentration-response curves. The maximal stimulatory
effect of 100 M HA amounted to 400 to 600% above basal. To calculate agonist efficacies, the maximum stimulatory effect of HA was set at 1.00, and the stimulatory effects
of other agonists were referred to this value. Data shown are the means  S.D. of three to six experiments performed in duplicate or triplicate. Efficacies and potencies,
respectively, of ligands at hH2R-GsS were compared with the corresponding parameters at gpH2R-GsS, and hH2R-C17Y-A271D-GsS, respectively, using the t test. The
control data for hH2R-GsS and gpH2R-GsS are identical with the control data for these constructs in Table 1 of Preuss et al. (2007).
Compound
hH2R-GsS gpH2R-GsS hH2R-C17Y-A271D-GsS
Efficacy EC50 Efficacy
a EC50
b Efficacya EC50
b
nM nM nM
1 HA 1.00 990  92 1.00 850  340 1.00 320  9			
2 DIM 0.85  0.02 910  430 0.94  0.06* 740  360 0.98  0.01*** 370  36	
3 AMT 0.91  0.02 190  50 1.04  0.01** 190  42 0.97  0.01** 65  6	
4 Suprahistaprodifen 0.54  0.08 240  41 0.43  0.02 310  62 0.61  0.02 320  11	
5 IMP 0.82  0.02 160  40 0.96  0.06* 18  9		 0.95  0.02** 37  5	
6 ARP 0.84  0.03 72  9 0.94  0.05* 7  1			 0.87  0.02 39  4		
7 BU-E-43 0.71  0.11 130  13 0.87  0.05 43  10			 0.73  0.01 150  6	
8 UR-PG214 0.91  0.08 130  45 0.94  0.05 25  10		 0.92  0.09 44  13	
9 UR-PG215 0.80  0.04 120  45 0.94  0.05* 14  4		 0.83  0.04 46  21
10 UR-PG222A 0.90  0.04 18  6 1.18  0.08** 5  1	 1.01  0.04** 13  5
11 UR-PG136 0.82  0.05 100  9 1.02  0.11* 29  10			 0.92  0.04* 66  5		
12 UR-AK57 0.86  0.05 15  4 0.97  0.18 14  6 0.78  0.03 21  10
13 UR-PG286A 0.55  0.06 49  9 0.82  0.02*** 12  8		 0.68  0.06 29  16
a Comparison with the efficacy at hH2R-GsS; *, p  0.05; **, p  0.01; ***, p  0.001.
b Comparison with the EC50 value at hH2R-GsS;
	, p  0.05; 		, p  0.01; 			, p  0.001.
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pool of ACmolecules in Sf9 cells and reflect an increased level
of constitutive activity of hH2R-C17Y-A271D-GsS, compared
with the wild-type fusion proteins. Similar reduced agonist-
responsiveness due to high constitutive activity was shown
for other aminergic GPCRs, e.g., 2AR-Gs fusion proteins
(Seifert et al., 1998a) and mutants of the 5-HT4 receptor
(Claeysen et al., 1999). At hH2R-C17Y-GsS much lower basal
AC activities and a much smaller stimulatory effect of GTP
were determined. In this case, GTP on its own caused only
26% of the effect with HA addition.
At hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS,
100 M HA reduced the basal AC activities in the absence of
added GTP (Fig. 4, A–C). Similar effects were observed at
2AR-GsS fusion proteins (Seifert et al., 1998b), and they are
due to dissociation of GDP from GsS following agonist bind-
ing to the receptor without subsequent binding of GTP. Gs-
GDP is more effective in activating AC than nucleotide-free
Gs; therefore, AC activities were decreased.
Discussion
Impaired Coupling in Membranes Expressing hH2R-
C17Y-GsS. In Sf9 cells expressing hH2R-C17Y-GsS, the
anti-FLAG and the anti-His6 antibodies recognized similarly
migrating proteins in SDS-PAGE that did not coincide with
the expected bands for monomeric H2R-GsS fusion proteins.
Measurement of GTP hydrolysis at hH2R-C17Y-GsS yielded
HA responses, but the increases in GTPase activity upon
agonist stimulation were much lower than in the wild-type
H2R-GsS species isoforms. Moreover, with this receptor mu-
tant, substantial stimulatory effects of HA and inhibitory
effects of IAPT on the GTP-dependent AC activity increases
were observed, but the basal AC activities and the stimula-
tory effects of GTP were largely reduced relative to wild-type
H2R-GsS species isoforms, and they were similar to the
values typical for Sf9 membranes expressing nonfused H2R
species (Houston et al., 2002). These controversial results of
hH2R-C17Y-GsS relative to hH2R-GsS and gpH2R-GsS im-
ply the following conclusions: The proteins expressed in Sf9
cells made up the amino acid sequence for hH2R-C17Y, and
they were functional in the test systems used. However,
coupling of hH2R-C17Y to GsS was much less efficient than
is characteristic for GPCR-Gs fusion proteins (Seifert et al.,
1999; Gille and Seifert, 2003). As a rationale, GsS could be
incorrectly expressed or degraded in Sf9 cells. Instead, hH2R-
C17Y possibly coupled to only a fraction of recombinant GsS
or to endogenous Gs-like G proteins with much lower effi-
ciency.
Increased Constitutive Activity in Membranes Ex-
pressing hH2R-C17Y-A271D-GsS. In membranes express-
ing hH2R-C17Y-A271D-GsS, high-efficiency coupling was
observed as GTPase activities were increased upon agonist
stimulation similar to hH2R-GsS and gpH2R-GsS. More-
over, with this receptor mutant enhanced basal GTPase ac-
tivities, increased potencies of the agonists as well as in-
creased inverse agonist efficacies of antagonists were
detected, representing the hallmarks of enhanced constitu-
tive activity compared with the wild-type proteins (Lefkowitz
et al., 1993). The determination of AC activity in Sf9 cell
membranes has previously shown to be an alternative and
sensitive system to quantify differences in the constitutive
activities of GPCRs (Seifert et al., 1998a). In membranes
expressing hH2R-C17Y-A271D-GsS the high basal AC activ-
TABLE 2
Potencies and inverse agonist efficacies of antagonists at hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS in the GTPase assay
Steady-state GTPase activity in Sf9 membranes expressing hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-A271D-GsS was determined as described under Materials and
Methods. Reaction mixtures contained Sf9 membranes expressing fusion proteins, 1 M HA as agonist and antagonists at concentrations from 1 nM to 1 mM as appropriate
to generate saturated competition curves. Competition curves were analyzed by nonlinear regression. To determine the inverse agonist efficacies (Inv. Ago. Eff.), the effects
of antagonists at fixed concentrations (10 M RAN, FAM, APT, and IAPT; 100 M CIM) on basal GTPase activity were assessed and referred to the stimulatory effect of 100
M HA (1.00). Data shown are the means  S.D. of three experiments performed in duplicates. KB values and inverse agonist efficacies, respectively, of antagonists at
hH2R-GsS were compared with the corresponding parameters at gpH2R-GsS and hH2R-C17Y-A271D-GsS, respectively, using the t test. The control data for hH2R-GsS and
gpH2R-GsS are identical with the control data for these constructs in Table 2 of Preuss et al. (2007).
Compound
hH2R-GsS gpH2R-GsS hH2R-C17Y-A271D-GsS
KB Inv. Ago. Eff. KB
a Inv. Ago. Eff. KB
a Inv. Ago. Eff.
nM nM nM
14 CIM 1700  430 0.08  0.01 1300  270 0.09  0.02 1400  19 0.25  0.04		
15 RAN 840  94 0.09  0.01 1000  170 0.08  0.01 1000  64 0.21  0.05		
16 FAM 48  10 0.10  0.02 38  3 0.10  0.01 29  2* 0.27  0.06		
17 APT 180  12 0.09  0.01 260  43* 0.09  0.01 200  31 0.26  0.05		
18 IAPT 35  7 0.10  0.01 26  4 0.10  0.01 12  2** 0.27  0.05			
a Comparison with the KB value at hH2R-GsS; *, p  0.05; **, p  0.01; ***, p  0.001.
b Comparison with Inv. Ago. Eff. at hH2R-GsS;
	, p  0.05; 		, p  0.01; 			, p  0.001.
TABLE 3
AC activities in Sf9 membranes expressing hH2R-GsS, gpH2R-GsS, hH2R-C17Y-GsS, and hH2R-C17Y-A271D-GsS
Basal AC activities and the effects of GTP and HA on AC activities in membranes expressing hH2R-C17Y-GsS and hH2R-C17Y-A271D-GsS were assessed and compared
with the corresponding values at hH2R-GsS and gpH2R-GsS. AC activity in Sf9 membranes was determined as described under Materials and Methods. Reaction mixtures
contained Sf9 membranes (20 g protein/tube) expressing fusion proteins and distilled water (basal), 10 M GTP, or 10 M GTP plus 100 M HA. Data shown are the
means  S.D. of three experiments performed in triplicates. To calculate the stimulatory effect of GTP (Rel. GTP Effect), the effect of 10 M GTP was referred to the effect
of 10 M GTP plus 100 M HA. The control data for hH2R-GsS and gpH2R-GsS are identical with the control data for these constructs in Table 3 of Preuss et al. (2007).
Construct Basal, ACActivity 10 M GTP, AC Activity 10 M GTP 	 100 M HA, AC Activity Rel. GTP Effect
pmol mg1 min1 %
hH2R-GsS 12.1  2.1 24.3  4.8 28.7  5.3 73
gpH2R-GsS 13.4  3.1 25.0  0.6 28.5  2.2 77
hH2R-C17Y-GsS 0.8  0.2 2.4  0.4 7.0  0.8 26
hH2R-C17Y-A271D-GsS 42.5  2.2 66.9  4.2 66.4  3.3 100
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ities and the strong AC activity increases upon stimulation
with GTP additionally reflect high constitutive activity com-
pared with hH2R-GsS, gpH2R-GsS, and hH2R-C17Y-GsS.
The discovery of increased constitutive activity at hH2R-
C17Y-A271D-GsS further supports the concept of an H-bond
between Tyr-17 in TM1 and Asp-271 in TM7 (Kelley et al.,
2001) as basis for the distinct pharmacological properties of
human and guinea pig H2Rs. Our data suggest that this
interhelical interaction stabilizes an active receptor confor-
mation not only when agonists are bound but also when
ligands are absent. However, gpH2R-GsS containing Tyr-17
and Asp-271 also was similarly constitutively active as
hH2R-GsS which is presumably due to additional intramo-
lecular interactions constraining the gpH2R in an inactive
conformation and thereby compensating for the activating
function of both residues.
Of interest, the tertiary structure of the 1b-AR contains
Lys-331 in TM7 corresponding to Ala-271 in hH2R. Strik-
ingly, 1b-AR mutants with Lys-331 exchanged by alanine or
glutamate were more constitutively active than wild-type
1b-AR (Porter et al., 1996), suggesting a general role of an
amino acid at this position for the activation mechanism of
related GPCRs.
Species Selectivity of Guanidines andNG-Acylguani-
dines at Wild-Type and Mutant H2R-GsS. The main in-
tention of this study was to elucidate the impact of Cys-17/
Tyr-17 and Ala-271/Asp-271 on the species selectivity ofN-[3-
(1H-imidazol-4-yl)propyl]guanidines and NG-acylated
imidazolypropylguanidines between hH2R and gpH2R. In our
GTPase activity experiments, some of these agonists were
more potent and more efficacious at hH2R-C17Y-A271D-GsS
than at hH2R-GsS, and some compounds were not selective.
Overall, the potencies and efficacies of the agonists were still
higher at gpH2R-GsS than at hH2R-C17Y-A271D-GsS. The
following conclusions can be drawn from these results.
First, both Tyr-17 and Asp-271 contribute to the enhanced
potencies and efficacies of guanidines andNG-acylguanidines
at the gpH2R. This investigation adds to a previous study at
an hH2R-A271D-GsS mutant conferring high potency to gua-
nidines without affecting the efficacies (Kelley et al., 2001).
However, the pharmacological differences between hH2R-
C17Y-A271D-GsS and gpH2R-GsS indicate that more than
these two amino acids determine the species selectivity of
agonists and will have to be identified in future mutagenesis
studies.
Second, the concept of ligand-specific conformations in H2R
species (Kelley et al., 2001; Kenakin, 2003; Xie et al., 2006a)
is further supported. The variable side chains of the com-
pounds distinctly interact with wild-type and mutant H2R-
GsS, which is represented by compounds 8 and 9 containing
a 2-thiazolyl group and being more potent at hH2R-C17Y-
A271D-GsS than at hH2R-GsS in contrast to compound 10
with a cyclohexyl group being similarly potent at both pro-
teins. The 5-methyl-1H-imidazol-4-yl group in IMP (5) pre-
sumably directly interacts with Asp-271 (Kelley et al., 2001),
yielding the high-potency increase of 4-fold at hH2R-C17Y-
A271D-GsS versus hH2R-GsS.
GPCRs with enhanced constitutive activity exhibit an in-
creased affinity for agonists with the affinity increase being
correlated with the efficacy of the ligand (Samama et al.,
1993). Accordingly, the parameter of constitutive activity not
only affects elevated potencies of small H2R agonists at
hH2R-C17Y-A271D-GsS but also potency increases of the
guanidines and NG-acylguanidines. Different magnitudes of
constitutive activity therefore add to the complexity of the
system for the analysis of species-selective ligand/GPCR in-
teractions. Moreover, inverse agonists are less potent at con-
stitutively active than at quiescent GPCRs (Kenakin, 2001).
Accordingly, 14 to 18 were expected to be less potent at the
more constitutively active hH2R-C17Y-A271D-GsS than at
hH2R-GsS. However, the potencies of inverse agonists were
not decreased, and 16 and 18 were even more potent at the
mutant receptor, assuming that not only guanidine-type ago-
nists but also inverse agonists could stabilize ligand-specific
conformations in H2R species isoforms.
Conclusions
In the present study, we demonstrate that an hH2R-GsS
fusion protein with mutations of Cys-173Tyr-17 in TM1 and
Ala-2713Asp-271 in TM7 displayed enhanced constitutive
activity compared with hH2R-GsS and gpH2R-GsS. We ad-
ditionally showed that an interaction between Tyr-17 and
Asp-271 in gpH2R contributes to the species-selective action
Fig. 4. Regulation of AC activities in Sf9 membranes expressing hH2R-GsS (A), gpH2R-GsS (B), hH2R-C17Y-A271D-GsS (C), and hH2R-C17Y-GsS
(D). AC activity in Sf9 membranes was determined as described under Materials and Methods. Reaction mixtures contained Sf9 membranes
expressing the proteins indicated on top of each panel and GTP at concentrations indicated at the abscissa. Reaction mixtures additionally contained
H2O (f), 100 M HA (Œ), or 10 M IAPT (). Data shown are the means  S.E.M. of one representative experiment performed in triplicates. The
statistical analysis of AC activities is provided in Table 3. Data were analyzed by nonlinear regression and were best fitted to sigmoidal concentration-
response curves. Please note the different scale of the ordinate in D. The control data for hH2R-GsS and gpH2R-GsS are identical with the control data
for these constructs in Fig. 6 of Preuss et al. (2007).
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of N-[3-(1H-imidazol-4-yl)propyl]guanidines and their NG-
acylated derivatives. Distinct potencies and efficacies of ago-
nists and inverse agonists further support the concept of
ligand-specific conformations in wild-type and mutant H2R-
GsS fusion proteins. A single point mutation of Cys-
173Tyr-17 was devoid of efficient GPCR-G protein coupling.
By analogy, point mutations of Phe-1533Leu-153 or Ile-
4333Val-433 in the hH1R (hH1R3gpH1R) resulted in func-
tional inactivity, whereas a Phe-1533Leu-153/Ile-4333Val-
433 double mutant was functionally active (Seifert et al.,
2003). The reasons for the annihilating effects of the single
point mutations hH1R and hH2R are not known, but they
illustrate the limitations of site-directed mutagenesis exper-
iments. The characterization of closely related wild-type
GPCR species isoforms is, therefore, an important alterna-
tive approach to relate distinct pharmacological properties to
relatively few molecular determinants.
Taken together, our mutational studies provide unique
insight into the molecular mechanisms of H2R functions and
will help us to find potent and selective agonists for the hH2R
that may be useful as positive inotropic drugs for the treat-
ment of severe congestive heart failure, as agents inducing
cell differentiation in acute myelogenous leukemia, and as
anti-inflammatory drugs.
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